Geovax Labs, Inc. · NASDAQ:GOVX
Geovax Labs — Q3 2022 Earnings Presentation
15 slides from Geovax Labs's earnings presentation, Nov 14, 2022
Slide 1: Q3 Corporate Update Conference Call
/ Q3 Corporate Update Conference call November 9, 2022 NASDAQ: GOVX
Slide 2: Forward Looking Statements
Forward Looking Statements ¢ Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private ‘Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumst
Slide 3: GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update
GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update Phase 2 Clinical Trials Advance for COVID-19 and Immuno-Oncology Company Secures Rights to NIH-MVA for Protection Against Monkeypox and Smallpox ATLANTA, GA, November 9, 2022 — GeoVax Labs, Inc. (Nasdaq: GOVX), a biote
Slide 4: Gedeptin Product Profile
Gedeptin® Product Profile Initi + Ph 1 Clinical results indicate tumor shrinkage and strong safety profile * Orphan Drug Status granted + Develop for further tumor indications * Develop in combination with ICls a rq Ceol
Slide 5: GEO-CM04S1 Product Profile
GEO-CM04S1 Product Profile Targeting the Immunocompromised populations as a primary vaccine As a more robust, durable booster for 1st generation COVID-19 vaccines Uniquely inducing both Antibody & Cellular immune responses Single-dose; durable; recognized safety; minimal refrigeration
Slide 6: 2022-2023 Clinical Trial Milestones
2022-2023 Clinical Trial Milestones Gedeptin® (Advanced Head and Neck Cancers) + 2022: * 2022: * 2023: + 2023: IND transferred to GeoVax : CRO (Allucent) engaged; Multi-site expansion of clinical trial : Regulatory discussions re expedited registration pathway : Completion of patient enrollment GEO-
Slide 7: Successful Capital Development
Successful Capital Development Cumulative YTD 2022 $37M $30M $10M Gear x>
Slide 8: GEO-CM04S1 Vaccine
GEO-CM04S1 Vaccine MVA as a vector supports the design and production of “next-generation” vaccines encoding multiple viral proteins + Spike protein as both the antibody and T-cell immunogen + Neutralizing antibodies induced after two doses + Nucleocapsid and Spike as the T-cell immunogen + Response
Slide 9: COVID Vaccine
COVID Vaccine GEO-CM04S1 — Phase 2 Clinical Trials Phase 2: For the Immunocompromised + Asa primary vaccine in direct comparison to the Pfizer mRNA vaccine + Most advanced trial to specifically evaluate a multi-antigen COVID-19 vaccine in patients with hematologic malignancies vs mRNA vaccine Phase
Slide 10: Monkeypox
Monkeypox Worldwide Monkeypox Cases peePrPaas of ss s S FO Ph a Wy FPP FF FF PPP wae x 10 Data source — Airfinity Limited
Slide 11: Monkeypox
Monkeypox CM04S1: COVID-19 + Monkeypox (validation in non-human primates; human-adults) Flavia Chiuppesi, John A. Zaia, Sandra Ortega Francisco, Minh Ly, Felix Wussow, Don J. Diamond Synthetic modified vaccinia Ankara vaccines confer potent monkeypox immunity in non- human primates and healthy adult
Slide 12: GeoVax Labs, Inc. Consolidated Statements of Operations Information
GeoVax Labs, Inc. Consolidated Statements of Operations Information (amounts in thousands, except share and per share information) ‘Three Months Ended September 30, Nine Months Ended September 30 2022 2021 2022 2021 Grant revenue $ - $ 30 $ 82 $ 221 Operating expenses Research and development 2,721
Slide 13: GeoVax Labs, Inc. Consolidated Balance Sheet Information
GeoVax Labs, Inc. Consolidated Balance Sheet Information (amounts in thousands, except share information) Assets Cash and cash equivalents Other current assets Total current assets Property and other assets, net Total assets Liabilities and stockholders’ equity Total liabilities Stockholders’ equity
Slide 14: Q&A Session
Slide 15: Slide 15